FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2626027566> ?p ?o ?g. }

• W2626027566 endingPage "50033" @default.
• W2626027566 startingPage "50023" @default.
• W2626027566 abstract "// Zhiguo Chen 1 , Rujian Zhu 2, 3 , Jiayi Zheng 4 , Chen Chen 2 , Chi Huang 2 , Junjie Ma 2 , Chen Xu 1 , Wei Zhai 1, 5 and Junhua Zheng 1 1 Department of Urology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China 2 Department of Urology, The Affiliated Shanghai Tenth People’s Hospital, Nanjing Medical University, Shanghai, China 3 Department of Urology, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, China 4 Department of Pathology, Shanghai Tenth People’s Hospital, Tongji University School of Medicine, Shanghai, China 5 Department of Urology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China Correspondence to: Wei Zhai, email: jacky_zw2002@hotmail.com Junhua Zheng, email: zhengjh0471@sina.com.cn Keywords: cryptotanshinone, renal cell carcinoma, cell proliferation, cell apoptosis, STAT3 Abbreviations: CPT: cryptotanshinone; RCC: renal cell carcinoma; STAT3: signal transducer and activator of transcription 3; DMSO: dimethyl sulfoxide Received: January 23, 2017     Accepted: May 04, 2017     Published: June 15, 2017 ABSTRACT It has been established that signal transducer and activator of transcription 3 serves as an oncoprotein in various human cancers; targeting it is therefore a reasonable approach for emerging cancer therapies. Cryptotanshinone, a natural compound extracted from the root of Salvia miltiorrhiza Bunge, has been identified as a potential STAT3 inhibitor. However, its functional role in renal cell carcinomas remains largely unknown. Therefore, we investigated the mode of action for cryptotanshinone. We found that cryptotanshinone substantially suppressed cancer cell growth while it promoted cell apoptosis by inhibiting the phosphorylation of STAT3 at Tyr705 and its blocking nuclear translocation. Coordinately, P-AKT, CyclinD1, C-MYC, MEKK2, and HGF were down-regulated and cell cycle progression was arrested at the G0/G1 phase, thereby attenuating cell proliferation. Moreover, the level of Cleaved-Caspase-3 was elevated while Bcl-2 and Survivin were down-regulated, accounting for the increased apoptosis. Furthermore, in vivo results revealed that cryptotanshinone effectively inhibits tumorigenesis in an A498-xenografted mouse model. Taken together, our data gives a more comprehensive understanding of how cryptotanshinone functions in renal cell carcinomas and demonstrates its potential as a powerful therapeutic approach to treat renal cell carcinomas." @default.
• W2626027566 created "2017-06-23" @default.
• W2626027566 creator A5005878171 @default.
• W2626027566 creator A5010729427 @default.
• W2626027566 creator A5036145443 @default.
• W2626027566 creator A5042980276 @default.
• W2626027566 creator A5059986506 @default.
• W2626027566 creator A5063253432 @default.
• W2626027566 creator A5066447753 @default.
• W2626027566 creator A5068272263 @default.
• W2626027566 creator A5070141658 @default.
• W2626027566 date "2017-06-15" @default.
• W2626027566 modified "2023-10-14" @default.
• W2626027566 title "Cryptotanshinone inhibits proliferation yet induces apoptosis by suppressing STAT3 signals in renal cell carcinoma" @default.
• W2626027566 cites W1548640328 @default.
• W2626027566 cites W1599834457 @default.
• W2626027566 cites W1821806054 @default.
• W2626027566 cites W1917630072 @default.
• W2626027566 cites W1955689398 @default.
• W2626027566 cites W1975398973 @default.
• W2626027566 cites W1979137164 @default.
• W2626027566 cites W1992224451 @default.
• W2626027566 cites W1994490964 @default.
• W2626027566 cites W2014630295 @default.
• W2626027566 cites W2019014345 @default.
• W2626027566 cites W2032890395 @default.
• W2626027566 cites W2035277147 @default.
• W2626027566 cites W2042708845 @default.
• W2626027566 cites W2043944756 @default.
• W2626027566 cites W2047868617 @default.
• W2626027566 cites W2059746321 @default.
• W2626027566 cites W2069204939 @default.
• W2626027566 cites W2075079121 @default.
• W2626027566 cites W2114831067 @default.
• W2626027566 cites W2117253810 @default.
• W2626027566 cites W2117924296 @default.
• W2626027566 cites W2131461955 @default.
• W2626027566 cites W2132591584 @default.
• W2626027566 cites W2132631303 @default.
• W2626027566 cites W2140411838 @default.
• W2626027566 cites W2164317031 @default.
• W2626027566 cites W2164638888 @default.
• W2626027566 cites W2199995479 @default.
• W2626027566 cites W2235523093 @default.
• W2626027566 cites W2291294190 @default.
• W2626027566 cites W2342038157 @default.
• W2626027566 cites W2398909362 @default.
• W2626027566 cites W2520363872 @default.
• W2626027566 doi "https://doi.org/10.18632/oncotarget.18483" @default.
• W2626027566 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5564825" @default.
• W2626027566 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28654902" @default.
• W2626027566 hasPublicationYear "2017" @default.
• W2626027566 type Work @default.
• W2626027566 sameAs 2626027566 @default.
• W2626027566 citedByCount "34" @default.
• W2626027566 countsByYear W26260275662017 @default.
• W2626027566 countsByYear W26260275662018 @default.
• W2626027566 countsByYear W26260275662019 @default.
• W2626027566 countsByYear W26260275662020 @default.
• W2626027566 countsByYear W26260275662021 @default.
• W2626027566 countsByYear W26260275662022 @default.
• W2626027566 countsByYear W26260275662023 @default.
• W2626027566 crossrefType "journal-article" @default.
• W2626027566 hasAuthorship W2626027566A5005878171 @default.
• W2626027566 hasAuthorship W2626027566A5010729427 @default.
• W2626027566 hasAuthorship W2626027566A5036145443 @default.
• W2626027566 hasAuthorship W2626027566A5042980276 @default.
• W2626027566 hasAuthorship W2626027566A5059986506 @default.
• W2626027566 hasAuthorship W2626027566A5063253432 @default.
• W2626027566 hasAuthorship W2626027566A5066447753 @default.
• W2626027566 hasAuthorship W2626027566A5068272263 @default.
• W2626027566 hasAuthorship W2626027566A5070141658 @default.
• W2626027566 hasBestOaLocation W26260275661 @default.
• W2626027566 hasConcept C126322002 @default.
• W2626027566 hasConcept C142724271 @default.
• W2626027566 hasConcept C143998085 @default.
• W2626027566 hasConcept C171958077 @default.
• W2626027566 hasConcept C188947578 @default.
• W2626027566 hasConcept C190283241 @default.
• W2626027566 hasConcept C204787440 @default.
• W2626027566 hasConcept C2776332195 @default.
• W2626027566 hasConcept C2777472916 @default.
• W2626027566 hasConcept C2778923194 @default.
• W2626027566 hasConcept C2781278892 @default.
• W2626027566 hasConcept C502942594 @default.
• W2626027566 hasConcept C54355233 @default.
• W2626027566 hasConcept C55493867 @default.
• W2626027566 hasConcept C556039675 @default.
• W2626027566 hasConcept C62112901 @default.
• W2626027566 hasConcept C71924100 @default.
• W2626027566 hasConcept C86803240 @default.
• W2626027566 hasConceptScore W2626027566C126322002 @default.
• W2626027566 hasConceptScore W2626027566C142724271 @default.
• W2626027566 hasConceptScore W2626027566C143998085 @default.
• W2626027566 hasConceptScore W2626027566C171958077 @default.
• W2626027566 hasConceptScore W2626027566C188947578 @default.
• W2626027566 hasConceptScore W2626027566C190283241 @default.
• W2626027566 hasConceptScore W2626027566C204787440 @default.

• next